Table 1.
Baseline characteristics of the study population according to the SIRI tertiles.
| Variables | T1: <0.63 | T2: 0.63–1.02 | T3: >1.02 | p Value |
|---|---|---|---|---|
| SIRI | 0.46 ± 0.12 | 0.81 ± 0.11 | 1.74 ± 1.06 | <.001 |
| Age (years) | 59 ± 10 | 60 ± 11 | 61 ± 11 | .019 |
| Male sex, n (%) | 380 (66.2) | 458 (79.5) | 485 (84.5) | <.001 |
| BMI (kg/m2) | 25.66 ± 2.99 | 25.84 ± 3.03 | 25.56 ± 3.22 | .297 |
| SBP (mmHg) | 130 ± 15 | 130 ± 16 | 130 ± 18 | .926 |
| DBP (mmHg) | 77 ± 9 | 76 ± 11 | 75 ± 12 | .022 |
| Risk factors | ||||
| Smoking, n (%) | 218 (38.0) | 271 (47.0) | 272 (47.4) | .001 |
| Hypertension, n (%) | 353 (61.5) | 370 (64.2) | 376 (65.6) | .353 |
| Diabetes, n (%) | 269 (46.9) | 263 (45.7) | 260 (45.3) | .856 |
| Dyslipidemia, n (%) | 439 (76.5) | 470 (81.6) | 469 (81.7) | .041 |
| Hyperuricaemia, n (%) | 108 (18.8) | 133 (23.1) | 130 (22.6) | .153 |
| Cancer, n (%) | 2 (0.3) | 6 (1.0) | 5 (0.9) | .367 |
| Previous MI, n (%) | 88 (15.3) | 119 (20.7) | 123 (21.4) | .017 |
| Previous PCI, n (%) | 104 (18.1) | 120 (20.8) | 117 (20.4) | .465 |
| Previous CVD, n (%) | 28 (4.9) | 29 (5.0) | 43 (7.5) | .105 |
| CKD, n (%) | 13 (2.3) | 15 (2.6) | 25 (4.4) | .088 |
| Heart failure, n (%) | 31(5.4) | 32 (5.6) | 59 (10.3) | .001 |
| LVEF (%) | 65 (61–68) | 65 (60–68) | 63 (58–68) | <.001 |
| Clinical presentation | ||||
| UA, n (%) | 484 (84.3) | 417 (72.4) | 378 (65.9) | <.001 |
| NSTEMI, n (%) | 57 (9.9) | 86 (14.9) | 77 (13.4) | .034 |
| STEMI, n (%) | 33 (5.7) | 73 (12.7) | 119 (20.7) | <.001 |
| GRACE risk score | 79 (65–91) | 82 (66–100) | 87 (73–107) | <.001 |
| Laboratory results | ||||
| Neutrophil (×106/μL) | 3.07 (2.61–3.61) | 3.94 (3.42–4.55) | 5.18 (4.40–6.06) | <.001 |
| Monocyte count (×106/μL) | 0.29 (0.22–0.33) | 0.35 (0.30–0.42) | 0.48 (0.40–0.58) | <.001 |
| Lymphocyte (×106/μL) | 1.89 (1.58–2.34) | 1.73 (1.42–2.14) | 1.57 (1.31–2.00) | <.001 |
| hs-CRP (mg/L) | 0.93 (0.45–2.05) | 1.32 (0.67–2.86) | 2.43 (0.92–6.68) | <.001 |
| Total cholesterol (mmol/L) | 4.23 ± 1.00 | 4.11 ± 0.96 | 4.10 ± 1.00 | .045 |
| LDL-C (mmol/L) | 2.48 ± 0.83 | 2.41 ± 0.79 | 2.43 ± 0.80 | .274 |
| HDL-C (mmol/L) | 1.08 ± 0.24 | 1.01 ± 0.22 | 1.00 ± 0.24 | <.001 |
| Triglycerides (mmol/L) | 1.43 (0.99–1.99) | 1.49 (1.04–2.10) | 1.45 (1.01–2.12) | <.001 |
| FPG (mmol/L) | 6.22 ± 1.64 | 6.32 ± 1.72 | 6.49 ± 1.79 | .026 |
| Glycosylated haemoglobin (%) | 6.10 (5.60–7.03) | 6.05 (5.60–7.10) | 6.10 (5.60–7.20) | .300 |
| eGFR (mL/min/1.73 m2) | 93.19 ± 14.04 | 93.87 ± 13.50 | 90.55 ± 15.70 | <.001 |
| Angiographic findings | ||||
| Left-main and/or multivessel disease, n (%) | 477 (83.1) | 486 (84.4) | 498 (86.8) | .216 |
| Chronic total occlusion, n (%) | 123 (21.4) | 122 (21.2) | 120 (20.9) | .977 |
| Lesions with length >20 mm, n (%) | 299 (52.1) | 284 (49.3) | 322 (56.1) | .068 |
| Bifurcation or trifurcation lesions, n (%) | 428 (74.6) | 440 (76.4) | 431 (75.1) | .761 |
| SYNTAX score | 18 (12–26) | 20 (12–28) | 22 (14–32) | <.001 |
| Procedural results | ||||
| Target vessel-LM, n (%) | 17 (6.3) | 21 (8.0) | 18 (6.9) | .751 |
| Target vessel-LAD, n (%) | 117 (43.5) | 143 (54.4) | 137 (52.7) | .026 |
| Target vessel-LCX, n (%) | 71 (26.4) | 75 (28.5) | 78 (30.0) | .651 |
| Target vessel-RCA, n (%) | 119 (44.2) | 102 (38.8) | 102 (39.2) | .363 |
| Complete revascularization, n (%) | 380 (66.2) | 358 (62.2) | 320 (55.7) | .001 |
| Periprocedural medications | ||||
| Low molecular weight heparin, n (%) | 368 (64.1) | 380 (66.0) | 389 (67.8) | .425 |
| Bivalirudin, n (%) | 69 (12.0) | 64 (11.1) | 63 (11.0) | .832 |
| GP IIb/IIIa receptor antagonist, n (%) (17.0) 42 (22.3) | 111 (19.3) | 129 (22.4) | 129 (22.5) | .336 |
| Prescription at discharge | ||||
| Aspirin, n (%) | 573 (99.8) | 575 (99.8) | 560 (97.6) | <.001 |
| Clopidogrel, n (%) | 519 (90.4) | 534 (92.7) | 530 (92.3) | .315 |
| Ticagrelor, n (%) | 55 (9.6) | 42 (7.3) | 44 (7.7) | .321 |
| Statins, n (%) | 574 (100.0) | 576 (100.0) | 574 (100.0) | .135 |
| ACEI/ARBs, n (%) | 256 (44.6) | 254 (44.1) | 320 (55.7) | <.001 |
| β-blockers, n (%) | 384 (66.9) | 403 (70.0) | 426 (74.2) | .024 |
| Oral anticoagulants, n (%) | 4 (0.7) | 4 (0.7) | 0 (0.0) | .135 |
| Nitroglycerin, n (%) | 412 (71.8) | 436 (75.7) | 444 (77.4) | .082 |
| Calcium channel blockers, n (%) | 131 (22.8) | 156 (27.1) | 145 (25.3) | .247 |
SIRI: systemic inflammatory response index; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MI: myocardial infarction; PCI: percutaneous coronary intervention; CVD: cerebrovascular disease; CKD: chronic kidney disease; LVEF: left ventricular ejection fraction; UA: unstable angina; NSTEMI: non ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; GRACE: Global registry of acute coronary events; hs-CRP: high sensitive C-reactive protein; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol; FPG: fasting plasma glucose; eGFR: estimated glomerular filtration rate; SYNTAX: Synergy between PCI with TAXUS and Cardiac Surgery; LM: left main artery; LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.